What does the NextGen MammaCore CanAssist test at Metropolis Healthcare include?
It analyzes key protein biomarkers along with clinical parameters to assess recurrence risk in breast cancer.
How does Metropolis Healthcare perform the MammaCore CanAssist test?
Metropolis Healthcare uses validated immunohistochemistry and proprietary algorithms to generate a precise risk score.
Who should consider this test at Metropolis Healthcare?
Patients with early-stage, hormone receptor–positive breast cancer being evaluated for chemotherapy suitability should consider this test.
Is fasting required for the MammaCore CanAssist test at Metropolis Healthcare?
No fasting is needed; the test is performed on tumor tissue samples.
How long do results take at Metropolis Healthcare?
Results are typically available within 10–15 working days due to detailed biomarker evaluation.
Can this test at Metropolis Healthcare help guide chemotherapy decisions?
Yes, it helps identify whether a patient is likely to benefit from adding chemotherapy to hormonal therapy.
How reliable is the CanAssist analysis performed by Metropolis Healthcare?
Metropolis Healthcare follows strict analytical standards, ensuring consistent, clinically meaningful results.
Does this test assist with long-term treatment planning at Metropolis Healthcare?
Yes, the recurrence risk score supports personalized treatment strategies and follow-up planning.